Lenvatinib‐induced pyoderma gangrenosum in a patient with hepatocellular carcinoma: A case report
2023; Wiley; Volume: 51; Issue: 2 Linguagem: Inglês
10.1111/1346-8138.16896
ISSN1346-8138
AutoresMirei Kanzaki, Akira Honda, Yasumasa Sawai, Kiyoka Suda, Ayumi Suda, Yasuhiro Kawachi,
Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoThe Journal of DermatologyEarly View LETTER TO THE EDITOR Lenvatinib-induced pyoderma gangrenosum in a patient with hepatocellular carcinoma: A case report Mirei Kanzaki, Corresponding Author Mirei Kanzaki [email protected] orcid.org/0000-0001-6950-5953 Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, Japan Correspondence Mirei Kanzaki, Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuou, Ami, Inashiki, Ibaraki 300-0395, Japan. Email: [email protected]Search for more papers by this authorAkira Honda, Akira Honda orcid.org/0000-0003-0902-8272 Joint Research Center, Tokyo Medical University Ibaraki Medical Center, Ami, Japan Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this authorYasumasa Sawai, Yasumasa Sawai Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this authorKiyoka Suda, Kiyoka Suda Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this authorAyumi Suda, Ayumi Suda Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this authorYasuhiro Kawachi, Yasuhiro Kawachi orcid.org/0000-0003-1106-9380 Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this author Mirei Kanzaki, Corresponding Author Mirei Kanzaki [email protected] orcid.org/0000-0001-6950-5953 Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, Japan Correspondence Mirei Kanzaki, Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuou, Ami, Inashiki, Ibaraki 300-0395, Japan. Email: [email protected]Search for more papers by this authorAkira Honda, Akira Honda orcid.org/0000-0003-0902-8272 Joint Research Center, Tokyo Medical University Ibaraki Medical Center, Ami, Japan Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this authorYasumasa Sawai, Yasumasa Sawai Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this authorKiyoka Suda, Kiyoka Suda Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this authorAyumi Suda, Ayumi Suda Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this authorYasuhiro Kawachi, Yasuhiro Kawachi orcid.org/0000-0003-1106-9380 Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, JapanSearch for more papers by this author First published: 12 July 2023 https://doi.org/10.1111/1346-8138.16896Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2017; 177: 72–83. 2Khoshnam-Rad N, Gheymati A, Jahangard-Rafsanjani Z. Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports. Anticancer Drugs. 2022; 33: e1–e8. 3Dohmen K. Severe ulcerative skin lesions due to Lenvatinib. Clin Gastroenterol Hepatol. 2020; 18:e113. 4Iwasa T, Adachi S, Ogiso H, Takada E, Mabuchi M, Suzuki Y, et al. Severe skin ulcer caused by taking lenvatinib after proton beam therapy. Clinical Journal of Gastroenterology. 2023. https://doi.org/10.1007/s12328-023-01802-0 Epub ahead of print. 5Miyagawa A, Adachi T, Takamiyagi S, Arakawa H, Matsushita M, Inazumi T. First case of lenvatinib-induced pyoderma gangrenosum: possible management with dose reduction. J Dermatol. 2021; 48: e221–e222. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation
Referência(s)